Aberdeen Group
NRIX icon

Aberdeen Group’s Nurix Therapeutics NRIX Stock Holding History

Aberdeen Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,537
Closed -$398K – 922
2022
Q3 		$398K Buy
+30,537
New +$483K ﹤0.01% 860
2021
Q4 		– Sell
-19,085
Closed -$572K – 1065
2021
Q3 		$572K Buy
+19,085
New +$589K ﹤0.01% 948

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Aberdeen Group's NRIX Position: Q4 2022 in Review

Aberdeen Group sold out of Nurix Therapeutics (NRIX) in Q4 2022, closing a stake of 30,537 shares — an estimated $398K sold.

Aberdeen Group first reported a position in NRIX in Q3 2021 and held it in 2 quarters. The position peaked at $572K in Q3 2021. 119 funds tracked by Wall St. Rank hold NRIX as of Q4 2022.

  • Aberdeen Group reported no remaining Nurix Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Aberdeen Group sold 30,537 Nurix Therapeutics shares in Q4 2022, an estimated $398K.
  • Aberdeen Group first reported a position in Nurix Therapeutics in Q3 2021 and held it in 2 quarters.
  • Aberdeen Group's Nurix Therapeutics position peaked at $572K in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2022.

Based on Aberdeen Group's 13F filing for Q4 2022, filed 10 Feb 2023.